PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
J. Lee, Jamie E. Chaft, A. Nicholas, Alexander Patterson, Saiama N. Waqar, Eric M. Toloza, Eric B. Haura, Dan J. Raz, Karen L. Reckamp, Robert E. Merritt, Dwight H. Owen, David J. Finley, Ciaran McNamee, Justin D. Blasberg, Edward B. Garon, Jason Mitchell, Robert C. Doebele, Frank A. Baciewicz, Misako Nagasaka, Harvey I. Pass, Katja Schulze, Sem H. Phan, Ann Johnson, Paul A. Bunn, Bruce E. Johnson, Mark G. Kris, David J. Kwiatkowski, Ignacio I. Wistuba, David P. Carbone, Valerie W. Rusch
Topics & Concepts
MedicineAtezolizumabOncologyStage (stratigraphy)Internal medicineCancerImmunotherapyBiologyPaleontologyPembrolizumabCancer Immunotherapy and BiomarkersLymphoma Diagnosis and TreatmentGastrointestinal Tumor Research and Treatment